公开(公告)号：US20140179721A1

公开(公告)日：2014-06-26

申请号：US14190618

申请日：2014-02-26

Applicant: AbbVie Inc.

Inventor： Joerg Rosenberg ,  Ulrich Reinhold ,  Bernd Liepold ,  Gunther Berndl ,  Joerg Breitenbach ,  Laman Alani ,  Soumojeet Ghosh

IPC: A61K47/32 ,  A61K47/26 ,  A61K31/513 ,  A61K31/427

CPC classification number: A61K47/32 ,  A61K9/10 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/427 ,  A61K31/513 ,  A61K47/26 ,  Y10S514/937

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 5° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract translation: 公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。 特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约5 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

公开(公告)号：US20150258093A1

公开(公告)日：2015-09-17

申请号：US14677611

申请日：2015-04-02

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter A. Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable

IPC: A61K31/513 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497

CPC classification number: A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Abstract translation: 本公开涉及包含抗病毒化合物的固体剂型和使用这些剂型来治疗抗病毒感染的方法。

公开(公告)号：US20140171481A1

公开(公告)日：2014-06-19

申请号：US14180531

申请日：2014-02-14

Applicant: AbbVie, Inc.

Inventor： Bernd Liepold ,  Tina Jung ,  Peter H?lig ,  Rudolf Schroeder ,  Nancy E. Sever ,  Justin S. Lafountaine ,  Brent D. Sinclair ,  Yi Gao ,  Jianwei Wu

IPC: A61K31/4025

CPC classification number: A61K31/4025 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1694 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/00

Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Abstract translation: 本发明的特征在于包含无定形化合物I的固体组合物。例如，化合物I可以配制成包含药学上可接受的亲水聚合物，优选药学上可接受的表面活性剂的无定形固体分散体

公开(公告)号：US09744170B2

公开(公告)日：2017-08-29

申请号：US15073767

申请日：2016-03-18

Applicant: AbbVie Inc.

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable

IPC: A61K31/513 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K9/24

CPC classification number: A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

公开(公告)号：US20170368066A1

公开(公告)日：2017-12-28

申请号：US15639424

申请日：2017-06-30

Applicant: AbbVie Inc.

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable

IPC: A61K31/513 ,  A61K47/38 ,  A61K31/4025 ,  A61K9/24 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32

CPC classification number: A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

公开(公告)号：US20160199374A1

公开(公告)日：2016-07-14

申请号：US15073767

申请日：2016-03-18

Applicant: AbbVie Inc.

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable

IPC: A61K31/513 ,  A61K47/38 ,  A61K31/427 ,  A61K47/32 ,  A61K31/497 ,  A61K31/4025

CPC classification number: A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

公开(公告)号：US10105365B2

公开(公告)日：2018-10-23

申请号：US15639424

申请日：2017-06-30

Applicant: AbbVie Inc.

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable ,  Susan George

IPC: A61K31/513 ,  A61K47/38 ,  A61K9/24 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K31/4025

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

公开(公告)号：US20170189426A1

公开(公告)日：2017-07-06

申请号：US15466673

申请日：2017-03-22

Applicant: AbbVie Inc.

Inventor： Claudia Packhaeuser ,  Norbert Steiger ,  Bernd Liepold ,  Drazen Kostelac ,  Martin Knobloch

IPC: A61K31/635 ,  A61K9/48 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K31/635 ,  A61K9/0053 ,  A61K9/146 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2095 ,  A61K9/4833

Abstract: The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders

公开(公告)号：US09333204B2

公开(公告)日：2016-05-10

申请号：US14677611

申请日：2015-04-02

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter A. Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable

IPC: A61K31/4965 ,  A01N43/54 ,  A01N43/36 ,  A61K31/513 ,  A61K47/32 ,  A61K47/38 ,  A61K9/24 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497

CPC classification number: A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Abstract translation: 本公开涉及包含抗病毒化合物的固体剂型和使用这些剂型来治疗抗病毒感染的方法。

公开(公告)号：US08691878B2

公开(公告)日：2014-04-08

申请号：US13674799

申请日：2012-11-12

Applicant: AbbVie Inc.

Inventor： Jeorg Rosenberg ,  Ulrich Reinhold ,  Bernd Liepold ,  Gunther Berndl ,  Joerg Breitenbach ,  Laman Alani ,  Soumojeet Ghosh

IPC: A61K8/72 ,  A61K9/20 ,  A61K9/48 ,  A61K31/425

CPC classification number: A61K47/32 ,  A61K9/10 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/427 ,  A61K31/513 ,  A61K47/26 ,  Y10S514/937

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract translation: 公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。 特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。